JP2024086827A5 - - Google Patents

Download PDF

Info

Publication number
JP2024086827A5
JP2024086827A5 JP2024062460A JP2024062460A JP2024086827A5 JP 2024086827 A5 JP2024086827 A5 JP 2024086827A5 JP 2024062460 A JP2024062460 A JP 2024062460A JP 2024062460 A JP2024062460 A JP 2024062460A JP 2024086827 A5 JP2024086827 A5 JP 2024086827A5
Authority
JP
Japan
Prior art keywords
uapc
cell
composition
cells
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024062460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024086827A (ja
JP7837068B2 (ja
Filing date
Publication date
Priority claimed from JP2020544206A external-priority patent/JP7591405B2/ja
Application filed filed Critical
Publication of JP2024086827A publication Critical patent/JP2024086827A/ja
Publication of JP2024086827A5 publication Critical patent/JP2024086827A5/ja
Application granted granted Critical
Publication of JP7837068B2 publication Critical patent/JP7837068B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024062460A 2018-02-21 2024-04-09 ユニバーサル抗原提示細胞およびその使用 Active JP7837068B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862633587P 2018-02-21 2018-02-21
US62/633,587 2018-02-21
JP2020544206A JP7591405B2 (ja) 2018-02-21 2019-02-21 ユニバーサル抗原提示細胞およびその使用
PCT/US2019/018989 WO2019165097A1 (en) 2018-02-21 2019-02-21 Universal antigen presenting cells and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020544206A Division JP7591405B2 (ja) 2018-02-21 2019-02-21 ユニバーサル抗原提示細胞およびその使用

Publications (3)

Publication Number Publication Date
JP2024086827A JP2024086827A (ja) 2024-06-28
JP2024086827A5 true JP2024086827A5 (https=) 2025-03-18
JP7837068B2 JP7837068B2 (ja) 2026-03-30

Family

ID=67686940

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020544206A Active JP7591405B2 (ja) 2018-02-21 2019-02-21 ユニバーサル抗原提示細胞およびその使用
JP2024062460A Active JP7837068B2 (ja) 2018-02-21 2024-04-09 ユニバーサル抗原提示細胞およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020544206A Active JP7591405B2 (ja) 2018-02-21 2019-02-21 ユニバーサル抗原提示細胞およびその使用

Country Status (18)

Country Link
US (1) US20200390815A1 (https=)
EP (1) EP3755347B1 (https=)
JP (2) JP7591405B2 (https=)
KR (1) KR20200123459A (https=)
CN (1) CN112292137A (https=)
AU (1) AU2019226021B2 (https=)
BR (1) BR112020016876A2 (https=)
CA (1) CA3091671A1 (https=)
DK (1) DK3755347T3 (https=)
ES (1) ES3035716T3 (https=)
FI (1) FI3755347T3 (https=)
MX (1) MX2020008801A (https=)
MY (1) MY210248A (https=)
PL (1) PL3755347T3 (https=)
PT (1) PT3755347T (https=)
SG (1) SG11202008008UA (https=)
TW (1) TWI899050B (https=)
WO (1) WO2019165097A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
MX2021006393A (es) * 2018-11-29 2021-10-13 Univ Texas Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
WO2020205359A1 (en) * 2019-03-29 2020-10-08 Board Of Regents, The University Of Texas System Methods for production of car-nk cells and use thereof
JP2022546101A (ja) * 2019-09-01 2022-11-02 エクスマ バイオテック コーポレイション リンパ球の改変および送達のための方法および組成物
EP4114400A4 (en) * 2020-03-05 2023-10-18 Exuma Biotech Corp. Methods and compositions for the delivery of modified lymphocyte aggregates
TW202300520A (zh) * 2021-05-19 2023-01-01 大陸商上海詩健生物科技有限公司 特異性識別baff-r的嵌合抗原受體分子及其應用
CN113832190A (zh) * 2021-09-24 2021-12-24 中海峡(福建)细胞生物科技有限公司 一种利用基因工程修饰的滋养细胞的制备方法及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5750356A (en) 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
US5939281A (en) 1996-09-16 1999-08-17 Case Western Reserve University Detecting alloreactivity
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6969609B1 (en) * 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
JP2002521489A (ja) 1998-07-27 2002-07-16 ユニバーシティ オブ アイオワ リサーチ ファウンデーション CpGオリゴヌクレオチドの立体異性体および関連する方法
WO2000023573A2 (en) 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
EP1673389A2 (en) 2003-10-10 2006-06-28 Xencor Inc. Novel variants of cd40l protein
AU2005250408B2 (en) * 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
PT1879599E (pt) 2005-04-20 2014-01-23 Hutchinson Fred Cancer Res Métodos, composições e artigos de fabrico para aumentar a capacidade de sobrevivência de células, tecidos, órgãos, e organismos
US9121008B2 (en) * 2005-08-31 2015-09-01 University Of Utah Research Foundation Development of natural killer cells and functional natural killer cell lines
US10611818B2 (en) * 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US9062287B2 (en) * 2009-09-11 2015-06-23 Takara Bio Inc. Process for production of natural killer cells
EP2841563B1 (en) * 2012-04-24 2019-06-12 Dan S. Kaufman Method for developing natural killer cells from stem cells
EP3578201B1 (en) * 2012-06-28 2023-04-19 University Of Central Florida Research Foundation Incorporated Methods and compositions for natural killer cells
JP6775426B2 (ja) * 2014-03-07 2020-10-28 エメルセル エスエーエス 臍帯血由来のプールnk細胞並びにがん及び慢性感染症の治療のためのこれらの用途
WO2015154012A1 (en) * 2014-04-03 2015-10-08 Memorial Sloan-Kettering Cancer Center Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
US9501570B2 (en) 2014-07-14 2016-11-22 Verizon Patent And Licensing Inc. Dynamic routing system
EP3223856B1 (en) * 2014-10-27 2025-09-24 University of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
CA2965521A1 (en) * 2014-10-31 2016-05-06 Baylor College Of Medicine Survivin specific t-cell receptor targeting tumor but not t cells
US11154572B2 (en) * 2015-06-05 2021-10-26 Board Of Regents, The University Of Texas System Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type
EP3138905A1 (en) * 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
CN115404196A (zh) * 2016-07-13 2022-11-29 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
CN109844099B (zh) * 2016-07-25 2024-01-02 美国政府(由卫生和人类服务部的部长所代表) 产生经修饰的自然杀伤细胞的方法及使用方法
WO2019090355A1 (en) * 2017-11-06 2019-05-09 Children's National Medical Center Cells expressing antibodies and methods of treatment using the same
MX2021006393A (es) * 2018-11-29 2021-10-13 Univ Texas Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.

Similar Documents

Publication Publication Date Title
JP2024086827A5 (https=)
Knorr et al. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy
Lee Cellular therapy: Adoptive immunotherapy with expanded natural killer cells
TWI836160B (zh) 製備用於t細胞治療之t細胞的方法
JP2024150721A (ja) B細胞悪性腫瘍及び他のがんの治療に有用な自己t細胞を産生する方法、並びにその組成物
Alvarez-Fernández et al. A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy
Ye et al. Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes
JP2025031794A5 (https=)
Delalat et al. 3D printed lattices as an activation and expansion platform for T cell therapy
JP2021505168A5 (https=)
JP2018524987A5 (https=)
Shook et al. Natural killer cell engineering for cellular therapy of cancer
CN1541113A (zh) 利用激活的t细胞使抗原提呈细胞成熟
JP2021513860A5 (https=)
FI3755347T3 (fi) Universaaleja antigeeniä esitteleviä soluja ja niiden käyttöjä
JP2022546537A (ja) T細胞療法のためのt細胞の調製方法
MX2023008162A (es) Composiciones y metodos para la expansion de celulas t y linfocitos infiltrantes del tumor.
Boucher et al. Large scale ex vivo expansion of Γδ T cells using artificial antigen-presenting cells
US20210087530A1 (en) Compositions and methods for culturing and expanding cells
Singh et al. Producing proT cells to promote immunotherapies
JPWO2021021963A5 (https=)
JPWO2020172328A5 (https=)
Wang et al. Alloreactive-free CAR-VST therapy: a step forward in long-term tumor control in viral context
EP4079375A1 (en) Method for producing t cells having cell surface markers for cd45ra+ and ccr7+
Dwarshuis et al. Functionalized microcarriers improve T cell manufacturing by facilitating migratory memory T cell production and increasing CD4/CD8 ratio